Regimen Reference Order - CNS - CARBOplatin + tamoxifen

ARIA: CNS – [CARBO + tamoxifen (Male Dosing)]
CNS – [CARBO + tamoxifen (Female Dosing)]

Planned Course: Until disease progression or unacceptable toxicity (1 cycle = 28 days)

Indication for Use: Recurrent Glioma

CVAD: At Provider's Discretion

Proceed with treatment if:

CARBOplatin:

- ANC equal to or greater than $1.5 \times 10^9/L$ AND Platelets equal to or greater than $100 \times 10^9/L$ tamoxifen:
- Continued throughout therapy regardless of CBC. If CARBOplatin is held for toxicity, tamoxifen is continued
 - Contact Physician if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements						
	Drug	Dose	CCMB Administration Guideline			
	Not Applicable					

Treatment Regimen – CNS – CARBOplatin + tamoxifen					
Establish primary solution 500 mL of: D5W					
Drug	Dose	CCMB Administration Guideline			
Cycle 1					
Days 1 to 28					
tamoxifen	Days 1 to 7: 20 mg	Orally twice daily (Self-administered at home)			
	Days 8 to 14: 40 mg				
	Days 15 to 21: 60 mg				
	Days 22 to 28: 80 mg				
Day 1 ONLY					
aprepitant	125 mg	Orally 1 hour pre-chemotherapy			
ondansetron	16 mg	Orally 30 minutes pre-chemotherapy			
dexamethasone	12 mg	Orally 30 minutes pre-chemotherapy			

CARBOplatin	AUC 5 mg/mL.min;	IV in D5W 250 mL over 30 minutes				
	maximum dose					
	750 mg					
	(see table below)					
Cycle 2 and Onwards						
Days 1 to 28						
tamoxifen	FOR MALE	Orally twice daily				
	PATIENTS:	(Self-administered at home)				
	100 mg					
	FOR FEMALE					
	PATIENTS:					
	80 mg					
Day 1 ONLY						
aprepitant	125 mg	Orally 1 hour pre-chemotherapy				
ondansetron	16 mg	Orally 30 minutes pre-chemotherapy				
dexamethasone	12 mg	Orally 30 minutes pre-chemotherapy				
CARBOplatin	AUC 5 mg/mL.min;	IV in D5W 250 mL over 30 minutes				
	maximum dose					
	750 mg					
	(see table below)					
tamoxifen available de	osage strength: 20 mg tabl	et				
Classification: Non-Cytotoxic, Hazardous						

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

All Cycles

• CBC, serum creatinine, urea, electrolytes, liver enzymes, total bilirubin, albumin, glucose, as per Physician Orders

Recommended Support Medications					
Drug	Dose	CCMB Administration Guideline			
aprepitant	80 mg	Orally once daily on Days 2 and 3			
dexamethasone	8 mg	Orally once daily on Days 2 and 3			
metoclopramide	20 mg	Orally every 4 hours as needed for nausea and vomiting			




DISCHARGE INSTRUCTIONS

- Instruct patient to continue taking anti-emetic(s) at home
- tamoxifen has potential for drug-drug interactions. Patient should notify clinic prior to starting any new medication
- · Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- CARBOplatin dose considerations:
 - CCMB CNS DSG uses actual body weight to calculate GFR
 - o CCMB CNS DSG uses a maximum CARBOplatin dose of 750 mg for this regimen
 - If calculated CARBOplatin dose differs more than 10% from prescribed CARBOplatin dose, contact the prescriber



AUC= Area Under Curve

The estimated creatinine clearance is based on limited evidence. Sound clinical judgment and interpretation of the estimation are required, because the equation above may not be appropriate for some patient populations (for example, acute renal failure).

